NCT05008744 Laser Photocoagulation of Communicating Vessels in Twin-to-Twin Transfusion Syndrome
| NCT ID | NCT05008744 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seattle Children's Hospital |
| Condition | Twin to Twin Transfusion as Antepartum Condition |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2021-10-01 |
| Primary Completion | 2031-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2021-10-01 with a primary completion date of 2031-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the use of diode laser photocoagulation of the communicating vessels in twin-to- twin transfusion syndrome (TTTS) with respect to maternal, fetal and neonatal outcomes.
Eligibility Criteria
Inclusion Criteria: * Single placenta (Monochorionic) * Polyhydramnios present in recipient twin (Greater than 8 cm maximum vertical pocket below 20 weeks and greater than a 10 cm pocket for greater than 20 weeks gestational age) * Oligohydramnios present in donor twin (Less than 2 cm maximum vertical pocket) * Prominent bladder in the recipient/ non-filling bladder in the donor * Thin dividing membrane Exclusion Criteria: * Patients unwilling to participate in the study or to be followed up * Presence of major congenital anomalies incompatible with survival * Active pre-term labor Ruptured membranes * Chorioamnionitis * Vaginal bleeding
Contact & Investigator
Martin P Walker, MD
PRINCIPAL INVESTIGATOR
Seattle Childrens Hospital
Frequently Asked Questions
Who can join the NCT05008744 clinical trial?
This trial is open to female participants only, studying Twin to Twin Transfusion as Antepartum Condition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05008744 currently recruiting?
Yes, NCT05008744 is actively recruiting participants. Contact the research team at martin.walker@seattlechildrens.org for enrollment information.
Where is the NCT05008744 trial being conducted?
This trial is being conducted at Seattle, United States, Seattle, United States.
Who is sponsoring the NCT05008744 clinical trial?
NCT05008744 is sponsored by Seattle Children's Hospital. The principal investigator is Martin P Walker, MD at Seattle Childrens Hospital. The trial plans to enroll 2,000 participants.